Faegre Baker Daniels Wins Patent Jury Trial for Coloplast

Faegre Baker Daniels announced today that on April 30, a federal court jury in Tacoma, Wash. returned a verdict of patent infringement in favor of Coloplast A/S (Coloplast) against Generic Medical Devices, Inc. (GMD), a start-up company based in Gig Harbor, Wash.

Coloplast's patent, U.S. Patent Number 7,621,864, entitled "Method for Treating Urinary Incontinence in Women and Implantable Device Intended to correct Urinary Incontinence" (‘864 patent) relates to a surgical method for treating stress urinary incontinence in women. The jury found that GMD had indirectly infringed six separate claims of the ‘864 patent when it marketed and sold its surgical tools and sling products to surgeons and other medical providers for use in the patented surgical method. The jury also found that the six asserted claims of the ‘864 patent were not invalid for lack of written description, lack of enablement, or obviousness. The court will soon schedule the briefing on Coloplast's motion for a permanent injunction.

"We are glad to see that the jury supported Coloplast's enforcement of its patent rights," said lead counsel David J.F. Gross.

In addition to Gross, the Faegre Baker Daniels trial team included Ted Budd, Tim Grimsrud, Chad Drown and Kate Razavi.

Coloplast develops products and services that make life easier for people with very personal and private medical conditions. Their business includes ostomy care, urology and continence care, and wound and skin care. They operate globally and employ more than 7,000 people.